ArticleJournal of contemporary brachytherapy2025
Isoflurane as a cost-effective alternative to sevoflurane for short-duration gynaecological brachytherapy: a randomised non-inferiority trial of emergence.
Article in Journal of contemporary brachytherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The optimal anaesthetic choice for gynaecological brachytherapy remains uncertain. While sevoflurane offers rapid recovery due to favourable pharmacokinetics, its higher cost limits affordability in resource-constrained settings. Isoflurane, a less expensive volatile agent, may be a cost-effective alternative if recovery profiles are comparable. Material and methods: We conducted a prospective, randomised, non-inferiority trial including 100 women with American Society of Anesthesiologists (ASA) physical status I-III undergoing ambulatory intracavitary brachytherapy. Participants were randomly allocated to maintenance anaesthesia with either isoflurane ( Results: Emergence times were similar between isoflurane and sevoflurane groups (7.13 ±1.60 min vs. 7.24 ±1.70 min; mean difference 0.12 min; 97.5% CI: 0.86 to -0.63), confirming non-inferiority of isoflurane. Secondary outcomes, including airway removal time, haemodynamics, cognitive scores, PACU stay and adverse events, showed no significant differences. Isoflurane administration cost was 61.6% lower compared to sevoflurane (22.2 ±2.77 INR vs. 57.8 ±9.35 INR; Conclusions: Isoflurane is non-inferior to sevoflurane for emergence time in short-duration gynaecological brachytherapy, with comparable recovery profiles. Its substantial cost advantage supports its use as an economical anaesthetic option in high-volume, resource-limited oncology settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.